Literature DB >> 19536518

Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes.

M S Wilke1, M A French, Y K Goh, E A Ryan, P J Jones, M T Clandinin.   

Abstract

AIMS/HYPOTHESIS: It is recommended that patients with diabetes reduce their intake of saturated fat and increase their intake of monounsaturated fat or carbohydrate. However, high-carbohydrate diets may result in higher saturated fatty acids in VLDL-triacylglycerol. This is attributed to de novo lipogenesis, although synthesis of specific fatty acids is rarely measured. The objective of this study was to examine the contribution of de novo fatty acid synthesis to VLDL-triacylglycerol composition. It was hypothesised that levels of total and de novo synthesised fatty acids would increase with increased carbohydrate intake in diabetic participants.
METHODS: Seven individuals with type 2 diabetes mellitus and seven matched non-diabetic controls consumed two diets differing in fat energy (lower fat <25%, higher fat >35%) for 3 days in a randomised crossover design. Blood samples were drawn before and 24 h after the ingestion of (2)H-labelled water.
RESULTS: In the control participants, the higher-fat diet resulted in a 40% reduction in VLDL-triacylglycerol fatty acids because of decreases in myristic, palmitic, palmitoleic and linoleic acids, but the opposite trend occurred in participants with diabetes. The lower-fat diet increased the fractional synthesis rate by 35% and 25% in the control and diabetes participants, respectively (range: 0-33%). Palmitate accounted for 71% of fatty acids synthesised (range: 44-84% total de novo synthesised fatty acids). CONCLUSIONS/
INTERPRETATION: (2)H incorporation was used for the first time in humans showing variability in the synthesis rate of specific fatty acids, even palmitic acid. A lower-fat diet stimulated saturated fatty acid synthesis at high rates, but no net stimulation of synthesis of any fatty acid occurred in the diabetes group. The implications of this finding for our understanding of lipid metabolism in diabetes require further investigation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19536518     DOI: 10.1007/s00125-009-1405-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  27 in total

1.  Total energy expenditure of elite synchronized swimmers measured by the doubly labeled water method.

Authors:  N Ebine; J Y Feng; M Homma; S Saitoh; P J Jones
Journal:  Eur J Appl Physiol       Date:  2000-09       Impact factor: 3.078

2.  Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.

Authors:  A Aarsland; D Chinkes; R R Wolfe
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Total fat intake modifies plasma fatty acid composition in humans.

Authors:  S K Raatz; D Bibus; W Thomas; P Kris-Etherton
Journal:  J Nutr       Date:  2001-02       Impact factor: 4.798

4.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Use of deuterium oxide to measure de novo fatty acid synthesis in normal subjects consuming different dietary fatty acid composition1.

Authors:  S D Konrad; S L Cook; Y K Goh; M A French; M T Clandinin
Journal:  Biochim Biophys Acta       Date:  1998-07-31

Review 6.  Dietary lipids influence insulin action.

Authors:  M T Clandinin; S Cheema; C J Field; V E Baracos
Journal:  Ann N Y Acad Sci       Date:  1993-06-14       Impact factor: 5.691

7.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets.

Authors:  Jean-Marc Schwarz; Peter Linfoot; Doris Dare; Karmen Aghajanian
Journal:  Am J Clin Nutr       Date:  2003-01       Impact factor: 7.045

8.  Dissociation of high density lipoprotein precursors from apolipoprotein B-containing lipoproteins in the presence of unesterified fatty acids and a source of apolipoprotein A-I.

Authors:  T A Musliner; M D Long; T M Forte; A V Nichols; E L Gong; P J Blanche; R M Krauss
Journal:  J Lipid Res       Date:  1991-06       Impact factor: 5.922

9.  Phosphatidylethanolamine methyltransferase: evidence for influence of diet fat on selectivity of substrate for methylation in rat brain synaptic plasma membranes.

Authors:  K M Hargreaves; M T Clandinin
Journal:  Biochim Biophys Acta       Date:  1987-04-03

10.  Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation.

Authors:  Cassandra E Forsythe; Stephen D Phinney; Maria Luz Fernandez; Erin E Quann; Richard J Wood; Doug M Bibus; William J Kraemer; Richard D Feinman; Jeff S Volek
Journal:  Lipids       Date:  2007-11-29       Impact factor: 1.880

View more
  22 in total

1.  Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity.

Authors:  Rebecca J Ford; Morgan D Fullerton; Stephen L Pinkosky; Emily A Day; John W Scott; Jonathan S Oakhill; Adam L Bujak; Brennan K Smith; Justin D Crane; Regje M Blümer; Katarina Marcinko; Bruce E Kemp; Hertzel C Gerstein; Gregory R Steinberg
Journal:  Biochem J       Date:  2015-05-15       Impact factor: 3.857

2.  Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes.

Authors:  Luke W Johnston; Zhen Liu; Ravi Retnakaran; Bernard Zinman; Adria Giacca; Stewart B Harris; Richard P Bazinet; Anthony J Hanley
Journal:  J Lipid Res       Date:  2018-07-09       Impact factor: 5.922

3.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

Authors:  Jennifer E Lambert; Maria A Ramos-Roman; Jeffrey D Browning; Elizabeth J Parks
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

4.  Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis.

Authors:  Joseph J Lee; Jennifer E Lambert; Yelena Hovhannisyan; Maria A Ramos-Roman; Justin R Trombold; David A Wagner; Elizabeth J Parks
Journal:  Am J Clin Nutr       Date:  2014-11-19       Impact factor: 7.045

5.  The childhood obesity epidemic as a result of nongenetic evolution: the maternal resources hypothesis.

Authors:  Edward Archer
Journal:  Mayo Clin Proc       Date:  2014-11-17       Impact factor: 7.616

6.  Estimated Elovl6 and delta-5 desaturase activities might represent potential markers for insulin resistance in Japanese adults.

Authors:  Kengo Moriyama; Yumi Masuda; Nana Suzuki; Chizumi Yamada; Noriaki Kishimoto; Shinji Takashimizu; Akira Kubo; Yasuhiro Nishizaki
Journal:  J Diabetes Metab Disord       Date:  2022-01-29

7.  Desaturation index versus isotopically measured de novo lipogenesis as an indicator of acute systemic lipogenesis.

Authors:  Scott V Harding; Kevin P Bateman; Brian P Kennedy; Todd C Rideout; Peter J H Jones
Journal:  BMC Res Notes       Date:  2015-02-23

8.  Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice.

Authors:  Jose Cordoba-Chacon; Neena Majumdar; Edward O List; Alberto Diaz-Ruiz; Stuart J Frank; Anna Manzano; Ramon Bartrons; Michelle Puchowicz; John J Kopchick; Rhonda D Kineman
Journal:  Diabetes       Date:  2015-05-26       Impact factor: 9.461

Review 9.  Dietary carbohydrates and fats in nonalcoholic fatty liver disease.

Authors:  Hannele Yki-Järvinen; Panu K Luukkonen; Leanne Hodson; J Bernadette Moore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-07-13       Impact factor: 46.802

10.  De novo lipogenesis and cholesterol synthesis in humans with long-standing type 1 diabetes are comparable to non-diabetic individuals.

Authors:  Jennifer E Lambert; Edmond A Ryan; Alan B R Thomson; Michael T Clandinin
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.